ANCA screen ELISA Kit

Catalog Number KA1083
96 assays
Version: 03

Intended for research use only
# Table of Contents

**Introduction** ................................................................. 3  
  Intended Use ................................................................. 3  
  Background ................................................................. 3  
  Principle of the Assay ..................................................... 3  

**General Information** .................................................... 4  
  Materials Supplied .......................................................... 4  
  Storage Instruction ......................................................... 4  
  Materials Required but Not Supplied .................................. 4  
  Precautions for Use .......................................................... 5  

**Assay Protocol** ............................................................... 7  
  Reagent Preparation ........................................................ 7  
  Sample Preparation .......................................................... 7  
  Assay Procedure ............................................................... 7  

**Data Analysis** ............................................................... 9  
  Calculation of Results ..................................................... 9  
  Performance Characteristics .............................................. 9  

**Resources** ........................................................................ 11  
  References ........................................................................ 11  
  Plate Layout ....................................................................... 12
Introduction

Intended Use

The ANCA Screen assay is an ELISA test system for the qualitative measurement of IgG class autoantibodies against PR3 and MPO in human serum or plasma. This product is intended for research use only.

Background

Anti-neutrophil cytoplasmic antibodies (ANCA) against proteinase 3 (PR3) or myeloperoxidase (MPO) are diagnostic markers for ANCA-associated vasculitides. PR3 is the landmark antigen in granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis). MPO differentiates microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). The test supports the differential method of these diseases when used in combination with other laboratory and clinical findings.

Principle of the Assay

A mixture of purified antigens PR3 and MPO is coated on to microwells. The determination is based on an indirect enzyme linked immune reaction with the following steps:
Specific antibodies in the sample bind to the antigen coated on the surface of the reaction wells. After incubation, a washing step removes unbound and unspecifically bound serum or plasma components. Subsequently added enzyme conjugate binds to the immobilized antibody-antigen-complexes. After incubation, a second washing step removes unbound enzyme conjugate. After addition of substrate solution the bound enzyme conjugate hydrolysates the substrate forming a blue coloured product. Addition of an acid stops the reaction generating a yellow end-product. The intensity of the yellow color correlates with the concentration of the antibody-antigen-complex and can be measured photometrically at 450 nm.
General Information

Materials Supplied

List of component

<table>
<thead>
<tr>
<th>Components</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Divisible microplate consisting of 12 modules of 8 wells each. Ready to use.</td>
<td>96 (12 x 8) wells</td>
</tr>
<tr>
<td>Control A-C: Control A (negative), B (cut-off) and C (positive), containing PR3, MPO antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN₃ 0.009%), yellow. Ready to use.</td>
<td>1.5 mL x 3 vials</td>
</tr>
<tr>
<td>Sample Buffer: Containing PBS, BSA, detergent, preservative NaN₃ 0.09%, yellow, 5x conc.</td>
<td>20 mL</td>
</tr>
<tr>
<td>Enzyme Conjugate: Containing anti-human IgG antibodies, HRP labelled; PBS, BSA, detergent, preservative ProClin 300 0.05%, light red. Ready to use.</td>
<td>15 mL</td>
</tr>
<tr>
<td>TMB Substrate: Containing 3,3', 5,5'- Tetramethylbenzidin, colorless. Ready to use.</td>
<td>15 mL</td>
</tr>
<tr>
<td>Stop solution: Contains acid. Ready to use.</td>
<td>15 mL</td>
</tr>
<tr>
<td>Wash Buffer: Containing Tris, detergent, preservative NaN₃ 0.09%; 50x conc.</td>
<td>20 mL</td>
</tr>
</tbody>
</table>

Storage Instruction

✓ Store test kit at 2-8°C in the dark.
✓ Do not expose reagents to heat, sun, or strong light during storage and usage.
✓ Store microplate sealed and desiccated in the clip bag provided.
✓ Unopened reagents are stable until expiration of the kit. See labels for individual batch.
✓ Diluted Wash Buffer and Sample Buffer are stable for at least 30 days when stored at 2-8°C. We recommend consumption on the same day.

Materials Required but Not Supplied

✓ Microplate reader capable of endpoint measurements at 450 nm; optional: reference filter at 620 nm
✓ Data reduction software
✓ Multi-channel dispenser or repeatable pipette for 100 µL
✓ Vortex mixer
✓ Pipettes for 10 µL, 100 µL and 1000 µL
✓ Laboratory timing device
✓ Distilled or deionised water
✓ Measuring cylinder for 1000 mL and 100 mL
✓ Plastic container for storage of the wash solution
✓ This ELISA assay is suitable for use on open automated ELISA processors. Each assay has to be
validated on the respective automated system. Detailed information is provided upon request.

**Precautions for Use**

- **Warning and Precautions**
  - All reagents of this kit are intended for research use only.
  - Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
  - Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
  - Avoid contact with the substrate TMB (3,3’,5,5’-Tetramethyl-benzidine).
  - Stop solution contains acid, classification is non-hazardous. Avoid contact with skin.
  - Control, sample buffer and wash solution contain sodium azide (NaN₃) 0.09% as preservative. This concentration is classified as non-hazardous.
  - Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.

During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:

- First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin, wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running water for at least 10 minutes. Get medical attention if necessary.
- Personal precautions, protective equipment and emergency procedures:
  - Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.
  - Exposure controls / personal protection: Wear protective gloves of nitrile rubber or natural latex. Wear protective glasses. Used according to intended use no dangerous reactions known.
  - Conditions to avoid: Since substrate solution is light-sensitive. Store in the dark.
  - For disposal of laboratory waste the national or regional legislation has to be observed.

Observe the guidelines for performing quality control in medical laboratories by assaying control sera.

- **Procedural Notes**
  - Do not use kit components beyond their expiration dates.
  - Do not interchange kit components from different lots and products.
  - All materials must be at room temperature (20-28°C) prior to use.
  - Prepare all reagents and samples. Once started, perform the test without interruption.
  - Double determinations may be done. By this means pipetting errors may become obvious.
  - Perform the assay steps only in the order indicated.
✓ Always use fresh sample dilutions.
✓ Pipette all reagents and samples into the bottom of the wells.
✓ To avoid carryover or contamination, change the pipette tip between samples and different kit controls.
   Wash microwells thoroughly and remove the last droplets of wash buffer.
✓ All incubation steps must be accurately timed.
✓ Do not re-use microplate wells.
Assay Protocol

Reagent Preparation

- Wash Buffer
  Dilute the contents of one vial of the buffered wash solution concentrate (50 x) with distilled or deionised water to a final volume of 1000 mL prior to use.
- Sample Buffer
  Prior to use dilute the contents (20 mL) of one vial of sample buffer 5x concentrate with distilled or deionised water to a final volume of 100 mL.

Sample Preparation

- Specimen collection, Storage and Handling
  - Collect whole blood specimens using acceptable techniques to avoid hemolysis.
  - Allow blood to clot and separate the serum or plasma by centrifugation.
  - Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
  - Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months.
  - Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
  - Testing of heat-inactivated sera is not recommended.

- Preparation of samples
  Dilute samples 1:100 before the assay: Put 990 µL of prediluted sample buffer in a polystyrene tube and add 10 µL of sample. Mix well.
  Note: Calibrators / Controls are ready to use and need not be diluted.

Assay Procedure

Prepare enough microplate modules for all calibrators / controls and samples.

1. Pipette 100 µL of calibrators, controls and prediluted samples into the wells.
2. Incubate for 30 minutes at room temperature (20-28°C).
3. Discard the contents of the microwells and wash 3 times with 300 µL of wash solution.
4. Dispense 100 µL of enzyme conjugate into each well.
5. Incubate for 15 minutes at room temperature.
6. Discard the contents of the microwells and wash 3 times with 300 µL of wash solution.
7. Dispense 100 µL of TMB substrate solution into each well.
8. Incubate for 15 minutes at room temperature.
9. Add 100 µL of stop solution to each well of the modules.
10. Incubate for 5 minutes at room temperature.
11. Read the optical density at 450 nm (reference 600-690 nm) and calculate the results. The developed colour is stable for at least 30 minutes. Read during this time.
Data Analysis

Calculation of Results

- Validation
  Test results are valid if the optical densities at 450 nm for calibrators / controls and the results for controls comply with the reference ranges indicated on the Certificate of Analysis enclosed in each test kit.
  If these quality control criteria are not met the assay run is invalid and should be repeated

- Calculation of Results
  For qualitative results the optical density (OD) of a sample is compared to the optical density of Control B:
  Negative: OD sample < OD Control B
  Positive: OD sample ≥ OD Control B
  For detailed results the optical density of a sample is expressed as Index value:
  Index = OD sample / OD Control B

Performance Characteristics

- Calibration
  This assay system is calibrated in relative arbitrary units, since no international reference preparation is available for this assay.

- Measuring range: not applicable.

- Expected values In a normal range study with samples from healthy blood donors the following ranges have been established with this ELISA assay:
  Cut-off: Index 1.0

- Interpretation of results
  Negative: Index < 1.0
  Positive: Index ≥ 1.0

- Linearity
  This is a qualitative assay. Requirements for quantitative assays are not applicable.

- Limit of detection: not applicable.

- Reproducibility
  Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below.
  Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 6 determinations in 5 different runs. Results for run-to-run precision are shown in the table below.
### Intra-Assay

<table>
<thead>
<tr>
<th>Sample</th>
<th>Mean Index</th>
<th>CV %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (MPO)</td>
<td>1.3</td>
<td>3.4</td>
</tr>
<tr>
<td>2 (PR3)</td>
<td>1.2</td>
<td>5.4</td>
</tr>
<tr>
<td>3 (MPO)</td>
<td>1.4</td>
<td>4.1</td>
</tr>
<tr>
<td>4 (PR3)</td>
<td>1.1</td>
<td>4.4</td>
</tr>
<tr>
<td>5 (MPO)</td>
<td>4.0</td>
<td>3.3</td>
</tr>
<tr>
<td>6 (PR3)</td>
<td>4.2</td>
<td>4.5</td>
</tr>
</tbody>
</table>

### Inter-Assay

<table>
<thead>
<tr>
<th>Sample</th>
<th>Mean Index</th>
<th>CV %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (MPO)</td>
<td>1.1</td>
<td>4.6</td>
</tr>
<tr>
<td>2 (PR3)</td>
<td>0.9</td>
<td>11.9</td>
</tr>
<tr>
<td>3 (MPO)</td>
<td>1.3</td>
<td>9.6</td>
</tr>
<tr>
<td>4 (PR3)</td>
<td>1.4</td>
<td>4.5</td>
</tr>
<tr>
<td>5 (MPO)</td>
<td>4.6</td>
<td>9.0</td>
</tr>
<tr>
<td>6 (PR3)</td>
<td>3.9</td>
<td>7.4</td>
</tr>
</tbody>
</table>

- **Interfering Substances**
  No interference has been observed with haemolytic (up to 1000 mg/dL) or lipemic (up to 3 g/dL triglycerides) sera or plasma, or bilirubin (up to 40 mg/dL) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparin). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

- **Study results**

<table>
<thead>
<tr>
<th></th>
<th>Pos</th>
<th>Neg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pos</td>
<td>39</td>
<td>1</td>
</tr>
<tr>
<td>Neg</td>
<td>2</td>
<td>43</td>
</tr>
</tbody>
</table>

Sensitivity: 95.1%
Specificity: 97.7%
Overall agreement: 96.5%
References

**Plate Layout**

<table>
<thead>
<tr>
<th></th>
<th>Sample 1</th>
<th>Sample 2</th>
<th>Sample 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Control A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>Control B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>Control C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>